"I would rather have aced the CKD and VD sub groups as we did and missed the CVD than vis-versa."
Are you sure about that?
Had we aced the CVD (assuming you mean BOM), we would be looking at a $20 stock today, and that would include the good data for CKD and VD subgroups as part of the overall CVOT trial.
Koo